Our leadership team is comprised of seasoned industry experts and financial specialists with extensive, in-depth experience in the health care and wellness industries.
Anthony G. Bruzzese, MD
Certified by both the American Board of Internal Medicine and the American Board of Radiology, Anthony G. Bruzzese, MD, provides patients with comprehensive diagnostic services at Toll Gate Radiology. He joined the practice in 1987 after completing his training. He also currently serves on the medical staff at Roger Williams Medical Center. As a Rhode Island native, Dr. Bruzzese remains committed to providing those in his community with the highest quality of care. He remains up-to-date with the latest developments in medicine through his membership in several professional organizations, including; American College of Radiology, RI Medical Society, RI Radiology Society, and the Association of American Physicians and Surgeons He previously served as President of the Radiological Society of RI and remains the Alternate Councilor and Councilor of the American College of Radiology. He also remains active with the local community as a previous member of the Board of Directors for the Opera Providence and RI Ballet Theatre. In 2008, Dr. Bruzzese was a recipient of the Top Doc award by Rhode Island Monthly. Dr. Bruzzese graduated with a Bachelor’s degree in Biochemistry and his medical degree from Brown University. He then completed postgraduate training through residencies in Internal Medicine at Rhode Island Hospital and in Diagnostic Radiology at Tufts-New England Medical Center Hospital and Boston VA Medical Center Hospital, where he served as Chief Resident during his final year. To further advance his training, Dr. Bruzzese also completed a fellowship in MRI at Tufts.
President & CEO
Mark McLaughlin has an extensive business background and financial expertise. With 10 years as an investment advisor at Lehman Brothers and 3 years at Oppenheimer & Company, Mr. McLaughlin gained experience across raising capital and business development. Thereafter, Mr. McLaughlin teamed up to manage money with Chris Cadbury, as a 50% Partner in Cadbury Asset Management, utilizing the proprietary indicators of Mr. Cadbury. Mr. Cadbury’s market indicators were ranked number one in the U.S. by Timer Digest for 2002 and 2011. Mr. McLaughlin continues to collaborate with Mr.Cadbury. Prior to becoming the CEO of ImmuDyne in 2011, Mr. McLaughlin played an integral role in successfully prosecuting several IP violations in ImmuDyne’s favor, as well as streamlining and improving the Company’s operating efficiencies to properly position the Company as It commercializes Its technologies. Mr. McLaughlin is a graduate of Holy Cross, Worcester, MA.
Sven Rohmann, MD, PhD, MBA
Global Chief Medical Officer
Dr. Sven Rohmann has an excellent track record across the scientific, academic, clinical practice, and commercial areas of the industry. He spent 10 years at Merck Serono where he gained a strong foothold in the pharmaceutical industry. During his tenure at Merck, he was involved in the successful licensing of Erbitux from ImClone and the establishment of Merck Oncology. Dr. Rohmann is a leading expert in innate immunity. In addition to his clinical expertise, he has worked across product development and marketing, as well as business development for immune health products. E.g. he was part of the management team of Biotec Pharmacon ASA, a public Norwegian company that developed soluble yeast beta-glucan for oncology indications and wound care. In 2010, Dr. Rohmann became the General Manager for Europe at Burrill & Company. He also serves on the board or in other executive functions for several small-sized companies in Europe and the USA. Prior to joining Burrill & Company, Dr. Rohmann worked as Venture Capital Fund Manager for Novartis Pharma AG, and as Managing Partner and General Partner at Nextech Venture AG. In addition, Dr. Rohmann served as CEO, CBO and CMO of five European biotech start-ups and gained board experience at several SME’s in Europe and the USA. Dr. Rohmann offers a unique blend of scientific, pharmaceutical, biotech, and venture capital knowledge. He has an extensive global network of contacts among health care providers as well as academic and government research administrators. His thorough knowledge of European research and regulatory policies combined with his global network provides great value to IMMUDYNE, allowing the company to expand its research activities and product portfolio globally. Dr. Rohmann received his Medical Degree from the University of Mainz, Germany, and his PhD from the Erasmus University, Rotterdam, Netherlands.
Joseph V. DiTrolio, MD
Chief Medical Officer, U.S.
Joseph V. DiTrolio, MD, is a Diplomate of the American Board of Urology, a Clinical Professor of Surgery, Division of Urology at New Jersey Medical School, the Treasurer, Board of Governors for the Stone Center of New Jersey, and the immediate past Chairman of the Department of Urology for the St. Barnabas Medical Center Healthcare System. Dr. DiTrolio has served as a medical consultant for Fortune 500 Healthcare companies including Novartis, Sanofi-Aventis, AstraZeneca, Allergan, et al. He is also the current Medical Director for OneMedPlace. He is the holder of several patents. Dr. DiTrolio’s experience across patient care, clinical research, and new product development brings great value to IMMUDYNE as the Company prepares to rollout new dietary supplement product lines through physician networks and practices. Dr. DiTrolio is a graduate of the University of Richmond, University of Paris, Sorbonne. He received his Medical Degree from New Jersey Medical School.